Trials / Completed
CompletedNCT05303324
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
A Phase 1, Randomized, Open-Label, 2-Way Crossover Study to Assess the Single-Dose Pharmacokinetics of ALXN1840 Enteric-Coated Tablets at 2 Dose Strengths in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1840 | Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period. |
Timeline
- Start date
- 2019-07-04
- Primary completion
- 2019-10-09
- Completion
- 2019-10-09
- First posted
- 2022-03-31
- Last updated
- 2023-08-02
- Results posted
- 2023-08-02
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05303324. Inclusion in this directory is not an endorsement.